| Q2 2024 |
35 |
$1.47B |
+$312M |
-$248M |
+$63.3M |
MRUS, NUVL, XENE, PCVX, ELVN
|
13F-HR |
8/14/2024, 04:25 PM |
| Q1 2024 |
39 |
$1.5B |
+$300M |
-$296M |
+$4.04M |
MRUS, VERA, NUVL, XENE, SYRE
|
13F-HR |
5/15/2024, 04:05 PM |
| Q4 2023 |
32 |
$1.14B |
+$265M |
-$167M |
+$97.3M |
MRUS, XENE, NUVL, VERA, RYTM
|
Restatement |
2/14/2024, 04:38 PM |
| Q3 2023 |
30 |
$856M |
+$154M |
-$120M |
+$34.4M |
MRUS, VERA, XENE, PCVX, COGT
|
13F-HR |
11/14/2023, 04:00 PM |
| Q2 2023 |
26 |
$890M |
+$223M |
-$133M |
+$90.2M |
MRUS, VERA, AKRO, XENE, COGT
|
13F-HR |
8/14/2023, 04:00 PM |
| Q1 2023 |
32 |
$657M |
+$171M |
-$107M |
+$63.6M |
XENE, VRDN, MRUS, COGT, BLU
|
13F-HR |
5/15/2023, 04:06 PM |
| Q4 2022 |
35 |
$664M |
+$167M |
-$118M |
+$48.8M |
XENE, VRDN, COGT, BLU, MRUS
|
13F-HR |
2/14/2023, 11:00 AM |
| Q3 2022 |
30 |
$601M |
+$137M |
-$59.7M |
+$77M |
COGT, XENE, VRDN, BLU, MRUS
|
13F-HR |
11/14/2022, 04:00 PM |
| Q2 2022 |
24 |
$473M |
+$117M |
-$50.5M |
+$66M |
MRUS, XENE, COGT, BLU, CYTK
|
13F-HR |
8/15/2022, 05:02 PM |
| Q1 2022 |
27 |
$448M |
+$110M |
-$46.3M |
+$63.5M |
MRUS, ACRS, BLU, ISEE, XENE
|
13F-HR |
5/16/2022, 04:00 PM |
| Q4 2021 |
25 |
$432M |
+$131M |
-$80.7M |
+$50.7M |
ISEE, MRUS, ACRS, XENE, CYTK
|
13F-HR |
2/14/2022, 04:07 PM |
| Q3 2021 |
29 |
$379M |
+$137M |
-$50.5M |
+$86.8M |
ISEE, ACRS, CYTK, DRNA, CCCC
|
13F-HR |
11/15/2021, 04:02 PM |
| Q2 2021 |
29 |
$287M |
+$75.4M |
-$45.8M |
+$29.6M |
ACRS, STSA, CELC, CCCC, CBAY
|
Restatement |
10/13/2021, 06:02 PM |
| Q1 2021 |
31 |
$251M |
+$74.3M |
-$34M |
+$40.3M |
ACRS, CCCC, KURA, STSA, FPRX
|
Restatement |
10/13/2021, 05:58 PM |
| Q4 2020 |
28 |
$184M |
$0 |
$0 |
|
CCCC, CNST, FPRX, KRON, ISEE
|
13F-HR |
2/16/2021, 04:13 PM |